Display options
Cite
Peres FF, Levin R, Almeida V, et al. Cannabidiol, among Other Cannabinoid Drugs, Modulates Prepulse Inhibition of Startle in the SHR Animal Model: Implications for Schizophrenia Pharmacotherapy. Front Pharmacol. 2016;7:303doi: 10.3389/fphar.2016.00303.
Peres, F. F., Levin, R., Almeida, V., Zuardi, A. W., Hallak, J. E., Crippa, J. A., & Abilio, V. C. (2016). Cannabidiol, among Other Cannabinoid Drugs, Modulates Prepulse Inhibition of Startle in the SHR Animal Model: Implications for Schizophrenia Pharmacotherapy. Frontiers in pharmacology, 7303. https://doi.org/10.3389/fphar.2016.00303
Peres, Fernanda F, et al. "Cannabidiol, among Other Cannabinoid Drugs, Modulates Prepulse Inhibition of Startle in the SHR Animal Model: Implications for Schizophrenia Pharmacotherapy." Frontiers in pharmacology vol. 7 (2016): 303. doi: https://doi.org/10.3389/fphar.2016.00303
Peres FF, Levin R, Almeida V, Zuardi AW, Hallak JE, Crippa JA, Abilio VC. Cannabidiol, among Other Cannabinoid Drugs, Modulates Prepulse Inhibition of Startle in the SHR Animal Model: Implications for Schizophrenia Pharmacotherapy. Front Pharmacol. 2016 Sep 09;7:303. doi: 10.3389/fphar.2016.00303. eCollection 2016. PMID: 27667973; PMCID: PMC5016523.
Copy Download .nbib Format: NLM
Share it on

Front Pharmacol. 2016 Sep 09;7:303. doi: 10.3389/fphar.2016.00303. eCollection 2016.

Cannabidiol, among Other Cannabinoid Drugs, Modulates Prepulse Inhibition of Startle in the SHR Animal Model: Implications for Schizophrenia Pharmacotherapy.

Frontiers in pharmacology

Fernanda F Peres, Raquel Levin, Valéria Almeida, Antonio W Zuardi, Jaime E Hallak, José A Crippa, Vanessa C Abilio

Affiliations

  1. Interdisciplinary Laboratory of Clinical Neurosciences, Department of Psychiatry, Escola Paulista De Medicina, Federal University of São PauloSão Paulo, Brazil; Department of Pharmacology, Escola Paulista De Medicina, Federal University of São PauloSão Paulo, Brazil.
  2. Department of Neuroscience and Behavior, University of São PauloRibeirão Preto, Brazil; National Institute for Translational Medicine (INCT-TM, CNPq)Ribeirão Preto, Brazil.

PMID: 27667973 PMCID: PMC5016523 DOI: 10.3389/fphar.2016.00303

Abstract

Schizophrenia is a severe psychiatric disorder that involves positive, negative and cognitive symptoms. Prepulse inhibition of startle reflex (PPI) is a paradigm that assesses the sensorimotor gating functioning and is impaired in schizophrenia patients as well as in animal models of this disorder. Recent data point to the participation of the endocannabinoid system in the pathophysiology and pharmacotherapy of schizophrenia. Here, we focus on the effects of cannabinoid drugs on the PPI deficit of animal models of schizophrenia, with greater focus on the SHR (Spontaneously Hypertensive Rats) strain, and on the future prospects resulting from these findings.

Keywords: SHR strain; animal models; cannabidiol; endocannabinoid system; prepulse inhibition of startle reflex; schizophrenia

References

  1. Front Pharmacol. 2014 Feb 06;5:10 - PubMed
  2. Biol Psychiatry. 2005 Mar 15;57(6):594-608 - PubMed
  3. Brain Res. 2009 Feb 9;1253:81-91 - PubMed
  4. Psychopharmacology (Berl). 2008 Aug;199(3):331-88 - PubMed
  5. Schizophr Res. 2007 Aug;94(1-3):29-36 - PubMed
  6. Schizophr Res. 2008 Apr;101(1-3):185-94 - PubMed
  7. Prog Neuropsychopharmacol Biol Psychiatry. 2011 Aug 15;35(7):1748-52 - PubMed
  8. Int J Neuropsychopharmacol. 2014 Oct 31;18(5):null - PubMed
  9. Pharmacol Biochem Behav. 2006 Jun;84(2):330-6 - PubMed
  10. Behav Brain Res. 2011 Sep 23;222(2):299-308 - PubMed
  11. Psychopharmacology (Berl). 2005 Jan;177(3):264-71 - PubMed
  12. Lipids Health Dis. 2003 Aug 19;2:5 - PubMed
  13. Psychol Med. 2009 Oct;39(10):1607-16 - PubMed
  14. Schizophr Res. 2007 Sep;95(1-3):134-42 - PubMed
  15. Psychopharmacology (Berl). 2001 Jul;156(2-3):234-58 - PubMed
  16. Psychopharmacology (Berl). 2007 Aug;193(2):215-23 - PubMed
  17. Behav Brain Res. 2011 Apr 15;218(2):280-7 - PubMed
  18. Neuropsychopharmacology. 2000 Sep;23(3):223-39 - PubMed
  19. Behav Pharmacol. 1997 Aug;8(4):364-72 - PubMed
  20. Am J Psychiatry. 1999 Jul;156(7):1046-51 - PubMed
  21. Eur J Pharmacol. 2000 Nov 17;408(2):161-8 - PubMed
  22. J Psychopharmacol. 2012 Oct;26(10):1317-32 - PubMed
  23. Jpn Circ J. 1963 Mar;27:282-93 - PubMed
  24. Am J Psychiatry. 1994 Mar;151(3):363-7 - PubMed
  25. Br J Psychiatry. 2009 Apr;194(4):371-2 - PubMed
  26. Neuroscience. 2001;103(1):9-15 - PubMed
  27. Arch Gen Psychiatry. 1994 Apr;51(4):273-9 - PubMed
  28. Schizophr Bull. 2009 Jul;35(4):748-59 - PubMed
  29. Transl Psychiatry. 2012 Mar 20;2:e94 - PubMed
  30. J Clin Psychiatry. 1995 Oct;56(10):485-6 - PubMed
  31. Methods Mol Biol. 2012;829:125-44 - PubMed
  32. Int J Neurosci. 2004 Sep;114(9):1063-84 - PubMed
  33. Neuropsychopharmacology. 2010 Feb;35(3):764-74 - PubMed
  34. Lancet. 2007 Nov 17;370(9600):1706-13 - PubMed
  35. Curr Drug Saf. 2011 Sep 1;6(4):237-49 - PubMed
  36. Exp Brain Res. 2006 Jul;172(4):556-60 - PubMed
  37. Pharmacol Biochem Behav. 1993 Mar;44(3):741-4 - PubMed
  38. Psychopharmacology (Berl). 2004 Sep;175(2):220-4 - PubMed
  39. Neuropsychopharmacology. 2007 Oct;32(10 ):2098-107 - PubMed
  40. Pharmacol Biochem Behav. 2011 Jul;99(1):22-8 - PubMed
  41. Lancet. 2010 Aug 14;376(9740):517-23 - PubMed
  42. Trends Pharmacol Sci. 2009 Oct;30(10):515-27 - PubMed
  43. Brain Stimul. 2013 Jul;6(4):490-9 - PubMed
  44. Biol Psychiatry. 2001 Oct 15;50(8):578-85 - PubMed
  45. Schizophr Res. 2007 Jan;89(1-3):225-31 - PubMed
  46. Neuropsychopharmacology. 2004 Nov;29(11):2108-14 - PubMed
  47. Pharmacol Biochem Behav. 2006 Mar;83(3):380-90 - PubMed
  48. Psychopharmacology (Berl). 1982;76(3):245-50 - PubMed
  49. Neuropsychopharmacology. 2006 Apr;31(4):795-803 - PubMed
  50. Biol Psychiatry. 2002 Oct 1;52(7):729-39 - PubMed
  51. Br J Pharmacol. 2011 Oct;164(4):1162-94 - PubMed
  52. Curr Pharm Des. 2012;18(32):4960-5 - PubMed
  53. Schizophr Res. 2011 Dec;133(1-3):133-42 - PubMed
  54. Neuropsychopharmacology. 2012 Apr;37(5):1216-23 - PubMed
  55. Psychopharmacology (Berl). 2008 Jun;198(3):375-85 - PubMed
  56. J Psychopharmacol. 2009 Nov;23(8):979-83 - PubMed
  57. Neuroreport. 1999 Jun 3;10 (8):1665-9 - PubMed
  58. Neuroimage. 2010 Oct 1;52(4):1505-13 - PubMed
  59. Behav Pharmacol. 2002 Feb;13(1):29-37 - PubMed
  60. Am J Med Genet B Neuropsychiatr Genet. 2008 Apr 5;147(3):279-84 - PubMed
  61. Psychopharmacology (Berl). 1993;111(3):339-44 - PubMed
  62. Arch Gen Psychiatry. 1999 Mar;56(3):277-81 - PubMed
  63. World J Biol Psychiatry. 2012 Jul;13(5):318-78 - PubMed
  64. Psychopharmacology (Berl). 1997 Aug;132(4):366-74 - PubMed
  65. Hypertension. 1992 May;19(5):419-24 - PubMed
  66. Eur Psychiatry. 2005 Jun;20(4):349-53 - PubMed
  67. Pharmacol Biochem Behav. 1995 Dec;52(4):649-54 - PubMed
  68. Brain Res Bull. 2006 Dec 11;71(1-3):301-10 - PubMed
  69. Psychopharmacology (Berl). 2003 Jan;165(2):128-35 - PubMed
  70. Eur J Pharmacol. 1974 Sep;28(1):172-7 - PubMed
  71. Prog Neuropsychopharmacol Biol Psychiatry. 2013 Mar 5;41:30-5 - PubMed
  72. Neuroimage. 2013 Oct 1;79:304-12 - PubMed
  73. Schizophr Res. 2009 Dec;115(2-3):215-21 - PubMed
  74. J Clin Psychopharmacol. 2002 Aug;22(4):359-65 - PubMed
  75. Eur Neuropsychopharmacol. 2010 Jan;20(1):25-36 - PubMed
  76. Neuropsychopharmacology. 2003 Oct;28(10 ):1760-9 - PubMed
  77. Prog Neuropsychopharmacol Biol Psychiatry. 2004 Mar;28(2):355-60 - PubMed
  78. Eur J Pharmacol. 2003 Feb 28;463(1-3):35-53 - PubMed
  79. Neuropsychopharmacology. 2004 Aug;29(8):1558-72 - PubMed
  80. Pharmacol Biochem Behav. 2004 Apr;77(4):839-45 - PubMed
  81. Hypertension. 1992 May;19(5):425-7 - PubMed
  82. Nat Rev Neurosci. 2013 Jun;14(6):417-28 - PubMed
  83. Schizophr Res. 2014 Mar;153(1-3):150-9 - PubMed
  84. Biol Psychiatry. 1999 Jul 1;46(1):56-72 - PubMed
  85. Br J Pharmacol. 2008 Jan;153(2):199-215 - PubMed
  86. Psychopharmacology (Berl). 2015 Aug;232(16):3057-65 - PubMed
  87. J Clin Psychiatry. 2014 Nov;75(11):e31 - PubMed
  88. Psychiatry Res. 2015 Oct 30;229(3):690-4 - PubMed
  89. Neuropsychopharmacology. 2011 Jul;36(8):1620-30 - PubMed
  90. Biol Psychiatry. 2010 May 15;67(10 ):974-82 - PubMed
  91. Schizophr Bull. 2009 May;35(3):493-508 - PubMed
  92. Eur J Pharmacol. 2005 Apr 11;512(2-3):199-205 - PubMed
  93. Neurosci Lett. 2006 Apr 10-17;397(1-2):88-92 - PubMed
  94. Lancet. 2009 Aug 22;374(9690):635-45 - PubMed
  95. Arch Gen Psychiatry. 2006 Dec;63(12):1325-35 - PubMed
  96. Int J Neuropsychopharmacol. 2010 Aug;13(7):861-76 - PubMed
  97. Behav Brain Res. 2011 Nov 20;225(1):15-22 - PubMed
  98. Mol Psychiatry. 2002;7(5):515-8 - PubMed
  99. Neuropsychopharmacology. 2006 Dec;31(12 ):2652-9 - PubMed
  100. Pharmacol Biochem Behav. 2009 Aug;93(2):91-6 - PubMed
  101. Psychopharmacology (Berl). 1991;104(2):260-4 - PubMed
  102. Biol Psychiatry. 2001 Sep 15;50(6):418-24 - PubMed
  103. Biol Psychiatry. 2000 Jan 1;47(1):61-70 - PubMed
  104. Behav Brain Res. 2006 Jan 6;166(1):101-9 - PubMed
  105. Behav Pharmacol. 2005 Sep;16(5-6):447-54 - PubMed
  106. Int J Neurosci. 2009;119(1):40-58 - PubMed
  107. Prim Care Companion CNS Disord. 2012;14(3):null - PubMed
  108. J Neurol Neurosurg Psychiatry. 1995 Feb;58(2):192-200 - PubMed

Publication Types